SenzaGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

SenzaGen şirketinin toplam hissedar öz sermayesi SEK89.3M ve toplam borcu SEK2.1M olup, bu da borç-öz sermaye oranını 2.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK109.2M ve SEK19.8M dir.

Anahtar bilgiler

2.3%

Borç/özkaynak oranı

SEK 2.06m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 42.61m
Eşitlik	SEK 89.34m
Toplam yükümlülükler	SEK 19.83m
Toplam varlıklar	SEK 109.18m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation

Jan 01

Recent updates

Shareholders Will Probably Hold Off On Increasing SenzaGen AB's (STO:SENZA) CEO Compensation For The Time Being

May 09

We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate

Nov 28

We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely

Jul 30

Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth

Apr 16

Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation

Jan 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SENZA 'nin kısa vadeli varlıkları ( SEK60.3M ) kısa vadeli yükümlülüklerini ( SEK17.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: SENZA şirketinin kısa vadeli varlıkları ( SEK60.3M ) uzun vadeli yükümlülüklerini ( SEK2.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SENZA şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SENZA şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 2.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SENZA şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: SENZA tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

SenzaGen Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

SenzaGen AB Share AK to Be Deleted from OTC Equity

We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate

We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely

Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation

Recent updates

Consensus EPS estimates upgraded to kr0.49 loss, revenue downgraded

Third quarter 2024 earnings released: kr0.08 loss per share (vs kr0.20 loss in 3Q 2023)

SenzaGen AB (publ) and Research Institute for Fragrance Materials Announces New Grant Worth SEK 3.0 Million

Consensus EPS estimates fall by 16%

Price target decreased by 7.2% to kr16.00

Second quarter 2024 earnings released: kr0.30 loss per share (vs kr0.31 loss in 2Q 2023)

SenzaGen AB to Report Fiscal Year 2024 Results on Feb 13, 2025

President & CEO recently bought kr51k worth of stock

Consensus EPS estimates upgraded to kr0.48 loss

New minor risk - Shareholder dilution

First quarter 2024 earnings released: kr0.13 loss per share (vs kr0.25 loss in 1Q 2023)

Shareholders Will Probably Hold Off On Increasing SenzaGen AB's (STO:SENZA) CEO Compensation For The Time Being

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

President & CEO recently bought kr63k worth of stock

New minor risk - Share price stability

SenzaGen AB to Report First Half, 2024 Results on Aug 15, 2024

First half 2023 earnings released: kr0.51 loss per share (vs kr0.56 loss in 1H 2022)

SenzaGen AB to Report Fiscal Year 2023 Results on Feb 14, 2024

Insufficient new directors

Full year 2022 earnings released: kr1.03 loss per share (vs kr1.35 loss in FY 2021)

SenzaGen AB (OM:SENZA) acquired 100% stake in Toxhub S.R.L. for €0.3 million.

First half 2022 earnings released: kr0.56 loss per share (vs kr0.65 loss in 1H 2021)

SenzaGen AB to Report Fiscal Year 2022 Results on Feb 16, 2023

SenzaGen AB to Report First Half, 2022 Results on Aug 18, 2022

SenzaGen AB Share AK to Be Deleted from OTC Equity

Independent Director recently bought kr98k worth of stock

Full year 2021 earnings released: kr1.35 loss per share (vs kr1.27 loss in FY 2020)

CEO & Director recently bought kr53k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

SenzaGen AB, Annual General Meeting, May 05, 2022

SenzaGen AB Broadens Non-Animal Offering for Medical Devices with More Tests and Tailored Consulting Services

CEO & Director recently bought kr58k worth of stock

We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate

Chief Executive Officer Axel Sjoblad has left the company

First half 2021 earnings released: kr0.65 loss per share (vs kr0.60 loss in 1H 2020)

We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely

SenzaGen AB Receives Positive ESAC Opinion for GARD®Skin as the First Genomic Test for Identifying Skin Sensitizers

Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth

New 90-day high: kr15.50

Full year 2020 earnings released: kr1.27 loss per share (vs kr3.11 loss in FY 2019)

SenzaGen AB to Report First Half, 2021 Results on Aug 19, 2021

New 90-day low: kr11.50

New 90-day low: kr12.65

Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation

New 90-day low: kr12.70

New 90-day low: kr15.75

New 90-day low: kr20.60

New 90-day high - kr25.90

SenzaGen AB to Report Fiscal Year 2020 Results on Feb 18, 2021

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin